Document Detail


Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens.
MedLine Citation:
PMID:  17198970     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RNA interference (RNAi) and small-molecule approaches are synergistic on multiple levels, from technology and high-throughput screen development to target identification and functional studies. Here, we describe the RNAi screening platform that we have established and made available to the community through the Drosophila RNAi Screening Center at Harvard Medical School. We then illustrate how the combination of RNAi and small-molecule HTS can lead to effective identification of targets in drug discovery.
Authors:
Norbert Perrimon; Adam Friedman; Bernard Mathey-Prevot; Ulrike S Eggert
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2006-10-30
Journal Detail:
Title:  Drug discovery today     Volume:  12     ISSN:  1359-6446     ISO Abbreviation:  Drug Discov. Today     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-01-02     Completed Date:  2007-04-16     Revised Date:  2007-12-03    
Medline Journal Info:
Nlm Unique ID:  9604391     Medline TA:  Drug Discov Today     Country:  England    
Other Details:
Languages:  eng     Pagination:  28-33     Citation Subset:  IM    
Affiliation:
Department of Genetics, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA. perrimon@receptor.med.harvard.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Drosophila / cytology,  genetics
Drug Delivery Systems / methods*
Drug Design
Drug Evaluation, Preclinical / methods*
RNA Interference*
RNA, Small Interfering / genetics
Grant Support
ID/Acronym/Agency:
R01GM067761/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/RNA, Small Interfering

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Enantioselective organocatalysis.
Next Document:  Multi-target therapeutics: when the whole is greater than the sum of the parts.